CAR T cells produced in vivo to treat cardiac injury.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study (CEBM Level 5)
PubMed 34990237 · doi:10.1126/science.abm0594
What was done
Researchers developed an in vivo approach to generate transient antifibrotic chimeric antigen receptor (CAR) T cells by delivering modified mRNA encapsulated in CD5-targeted lipid nanoparticles (LNPs). The therapeutic efficacy of these reprogrammed T cells was evaluated in a mouse model of heart failure.
What was found
The targeted LNPs delivered modified mRNA to T lymphocytes in vivo, producing functional and transient CAR T cells that exhibited trogocytosis, retained target antigen, and accumulated in the spleen. Treatment with modified mRNA-targeted LNPs reduced fibrosis and restored cardiac function after injury. No quantitative data or statistical values are reported in the abstract.
Why it matters
This study provides proof of concept for directly generating functional CAR T cells in vivo using targeted mRNA nanoparticles, which could bypass the logistical and financial hurdles of ex vivo cell manufacturing for non-oncologic conditions.
Limits
The findings are limited to a mouse model, and translatability to human cardiac disease is unproven. The abstract omits sample sizes, quantitative effect sizes, duration of benefit, and assessment of potential off-target delivery or toxicity.
Cited by
- supports Researchers at a University of Pennsylvania spinout developed targeted lipid nanoparticles that bind T cells in the bloodstream to deliver mRNA encoding CARs and generate CAR T cells in vivo.